Form 4: Bristol-Myers Squibb Executive Sandra Leung Reports Changes in Beneficial Ownership

EVP and General Counsel of Bristol-Myers Squibb, Sandra Leung, reports transactions involving common stock and market share units, including vesting, adjustments, and shares withheld for taxes.

Summary

• Sandra Leung, EVP and General Counsel of Bristol-Myers Squibb, filed a Form 4 detailing changes in her beneficial ownership of company stock.
• The reported transactions occurred on March 10, 2024, and involve common stock and market share units.
• Several transactions involved the vesting of market share units granted in previous years (2020, 2021).
• Some market share units were adjusted downward or canceled due to performance factors not meeting minimum payout thresholds.
• Shares were also withheld for payment of taxes upon the vesting of awards at a price of $53.79.
• Leung also acquired performance shares related to the 2021-2023 Long-Term Performance Award.
• After these transactions, Leung directly owns 347,385.333 shares of common stock and indirectly owns 7,285.12 shares through the BMS Savings and Investment Program and 93,436 shares through a Spousal Lifetime Access Trust (SLAT).
• She also holds various market share units that will vest in the future.

Sentiment

Score: 6

Explanation: The sentiment is neutral. The document primarily reports routine transactions related to executive compensation. While some performance targets were not fully met, leading to adjustments, the overall tone is factual and does not indicate significant positive or negative developments.

Positives

• The vesting of market share units and performance shares indicates that certain performance goals were met, at least partially, leading to the distribution of these awards.

Negatives

• The downward adjustments and cancellations of market share units suggest that some performance targets were not fully achieved, as the minimum payout factor of 80% was not met for some grants.

Risks

• Fluctuations in Bristol-Myers Squibb's stock price could impact the value of Leung's holdings and future payouts from market share units.
• Changes in company performance could affect the payout factors applied to market share units, potentially reducing their value.
• Tax liabilities associated with vesting awards could impact the overall financial benefit to the reporting person.

Future Outlook

The document indicates future vesting dates for market share units, extending to 2028, and distribution of performance shares in 2027, suggesting continued long-term incentives for the reporting person.

Industry Context

Form 4 filings are a routine part of executive compensation and provide transparency into the alignment of management's interests with those of shareholders. The vesting of market share units and performance shares is a common practice in the pharmaceutical industry to incentivize long-term performance.

Comparison to Industry Standards

• Executive compensation packages in the pharmaceutical industry often include a mix of salary, stock options, restricted stock units (RSUs), and performance-based awards.
• Companies like Pfizer, Merck, and Johnson & Johnson also utilize similar long-term incentive plans tied to company performance and shareholder return.
• The specific payout factors and performance metrics used in Bristol-Myers Squibb's market share unit program are likely benchmarked against industry peers to ensure competitiveness and alignment with strategic goals.
• The minimum payout factor of 80% for some market share units is a common threshold used to ensure that payouts are only made when a certain level of performance is achieved.

Stakeholder Impact

• The reported transactions provide transparency to shareholders regarding executive compensation and alignment of interests.
• The vesting of equity awards can be seen as a positive sign, indicating that the company is achieving certain performance goals.
• However, the adjustments to market share units may raise concerns about whether all performance targets are being consistently met.

Key Dates